RT Journal Article
SR Electronic
T1 Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.14.21266318
DO 10.1101/2021.11.14.21266318
A1 Li, Rui
A1 Liu, Hanting
A1 Fairley, Christopher K
A1 Zou, Zhuoru
A1 Xie, Li
A1 Li, Xinghui
A1 Shen, Mingwang
A1 Li, Yan
A1 Zhang, Lei
YR 2021
UL http://medrxiv.org/content/early/2021/11/14/2021.11.14.21266318.abstract
AB Background Over 86% of older adults aged ≥65 years are fully vaccinated against SARS-COV-2 in the United States (US). Waning protection of the existing vaccines promotes the new vaccination strategies, such as providing a booster shot for those fully vaccinated.Methods We developed a decision-analytic Markov model of COVID-19 to evaluate the cost-effectiveness of a booster strategy of Pfizer-BioNTech BNT162b2 (administered 6 months after 2nd dose) in those aged ≥65 years, from a healthcare system perspective.Findings Compared with 2-doses of BNT162b2 without a booster, the booster strategy in a 100,000 cohort of older adults would incur an additional cost of $3.4 million, but save $6.7 million in direct medical costs in 180 days. This corresponds to a benefit-cost ratio of 1.95 and a net monetary benefit of $3.4 million. Probabilistic sensitivity analysis indicates that with a COVID-19 incidence of 9.1/100,000 person-day, a booster strategy has a high chance (67%) of being cost-effective. The cost-effectiveness of the booster strategy is highly sensitive to the population incidence of COVID-19, with a cost-effectiveness threshold of 8.1/100,000 person-day. This threshold will increase with a decrease in vaccine and booster efficacies. Doubling the vaccination cost or halving the medical cost for COVID-19 treatment alone would not alter the conclusion of cost-effectiveness, but certain combinations of the two might render the booster strategy not cost-effective.Interpretation Offering BNT162b2 boosters to older adults aged ≥65 years in the US is likely to be cost-effective. Less efficacious vaccines and boosters may still be cost-effective in settings of high SARS-COV-2 transmission.Funding National Natural Science Foundation of China. Berlina and Bill Gates FoundationCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe work is supported by the Bill & Melinda Gates Foundation. LZ is supported by the National Natural Science Foundation of China (Grant number: 81950410639); Outstanding Young Scholars Funding (Grant number: 3111500001); Xi'an Jiaotong University Basic Research and Profession Grant (Grant number: xtr022019003 and xzy032020032) and Xi'an Jiaotong University Young Talent Support Grant (Grant number: YX6J004). MS was supported by the National Natural Science Foundation of China (Grant number: 12171387, 11801435), China Postdoctoral Science Foundation (Grant number: 2018M631134, 2020T130095ZX); the Fundamental Research Funds for the Central Universities (Grant number: xjh012019055); Natural Science Basic Research Program of Shaanxi Province (Grant number: 2019JQ-187), Young Talent Support Program of Shaanxi University Association for Science and Technology (Grant number: 20210307); XL was supported by the Special emergency public health safety project of Shaanxi Provincial Education Department (Grant number: 20JG007).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable